First Proof for Rituximab in IgG4-Related Disease Medscape SAN DIEGO — Rituximab (Rituxan, Genentech) is a potential treatment option in the multiorgan fibroinflammatory disorder known as immunoglobulin G4-related disease (IgG4), according to researchers reporting first evidence. "New therapeutic strategies ... |
